

Unanswered Questions in the Genetic Basis of Primary Aldosteronism

Author

Ute I. Scholl

Affiliation

Department of Nephrology, Medical School, Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany

Key words

aldosterone-producing adenoma, bilateral adrenal hyperplasia, genetics, familial hyperaldosteronism

received 04.09.2017

accepted 14.09.2017

Bibliography

DOI <https://doi.org/10.1055/s-0043-120066>

Published online: 24.10.2017

Horm Metab Res 2017; 49: 963–968

© Georg Thieme Verlag KG Stuttgart · New York

ISSN 0018-5043

Correspondence

Ute I. Scholl M.D.

Department of Nephrology

Medical School

Heinrich Heine University

Moorenstraße 5

40225 Düsseldorf

Germany

Tel.: +49/211/81 04086, Fax: +49/211/81 015 04086

ute.scholl@med.uni-duesseldorf.de

ABSTRACT

Over the past six years, the genetic basis of a significant fraction of primary aldosteronism (PA) cases has been solved. Breakthrough discoveries include the role of somatic variants in the *KCNJ5*, *CACNA1D*, *ATP1A1*, and *ATP2B3* genes as causes of aldosterone-producing adenomas (APAs), and the recognition of three novel hyperaldosteronism syndromes with germline variants in the *KCNJ5*, *CACNA1D*, and *CACNA1H* genes. The description of somatic variants in *CACNA1D* and *ATP1A1* in aldosterone-producing cell clusters (APCCs) suggests that these clusters are precursors of some aldosterone-producing adenomas. Yet, a number of questions remain unanswered. These include the genetic basis of about 40% of APAs without somatic variants in known genes. Do technical issues explain this finding, or are the unexplained APAs due to somatic copy number variation or rare variants in thus-far undiscovered genes? Similarly, the role of *CTNNB1* (beta catenin) variants in APA pathogenesis is still unclear. The major question to be solved is the genetic basis of bilateral adrenal hyperplasia (BAH). Is BAH due to the bilateral occurrence of APCCs, to germline variants, or perhaps due to unknown serum factors? Lastly, the etiology of unsolved cases of apparently familial hyperaldosteronism remains to be discovered. It is expected that genetic studies over the next few years will lead to answers to at least some of the questions raised.

Abbreviations

ACTH	Adrenocorticotrophic hormone
APA	Aldosterone-producing adenoma
APCC	Aldosterone-producing cell clusters
ATP1A1	ATPase Na ⁺ /K ⁺ Transporting Subunit Alpha 1
ATP2B3	ATPase Plasma Membrane Ca ²⁺ Transporting 3
BAH	Bilateral adrenal hyperplasia
CACNA1D	Calcium channel, voltage-dependent, L type, alpha 1D subunit
CACNA1H	Calcium channel, voltage-dependent, T type, alpha 1H subunit
CNV	Copy number variation
CYP11B1	Cytochrome P450, family 11, subfamily B, polypeptide 1
CYP11B2	Cytochrome P450, family 11, subfamily B, polypeptide 2

FH	Familial hyperaldosteronism
GRA	Glucocorticoid-remediable aldosteronism
KCNJ5	Potassium channel, inwardly rectifying subfamily J, member 5
PA	Primary aldosteronism
PASNA	Primary aldosteronism, seizures, and neurologic abnormalities
SNV	Single nucleotide polymorphism

Introduction

Primary aldosteronism (PA) is considered the most common cause of secondary hypertension. A recent study reported a prevalence of about 6% [1] in primary care, with higher prevalence among severely hypertensive cases. The prevalence in hypertension referral

centers is about 6–10% [2–4]. PA is characterized by excessive production of the adrenal steroid hormone aldosterone despite suppressed levels of its upstream regulator, the aspartyl protease renin, and normal or low serum potassium levels. Aldosterone-producing adenomas (APAs, with single or multiple nodules [5]) account for about 30% of cases, and bilateral adrenal hyperplasia for about 60% [4]. Diffuse unilateral hyperplasia is less common [6], whereas malignancy [7] and familial hyperaldosteronism (FH) [8] are considered rare.

Major progress has been made in understanding the genetic basis of PA over the past six years, but many questions remain unanswered [9]. This brings to mind U.S. Secretary of Defense Donald Rumsfeld's famous statement: "...as we know, there are known knowns; there are things we know we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns – the ones we don't know we don't know" [10]. These three aspects of the genetics of PA will be covered in this review.

The Known Knowns

About 40% of APAs are caused by one of two somatic (tumor specific) variants in the *KCNJ5* gene, and other variants are very rare [11–13]. *KCNJ5* encodes an inward rectifier potassium channel. The disease-causing variants are located within or close to the selectivity filter of the channel and cause abnormal sodium permeability. Sodium influx through mutant channels leads to cellular depolarization, activation of voltage-dependent calcium channels, calcium influx and activation of the pathways that regulate aldosterone production [11, 14]. Approximately 10% of tumors carry somatic variants in the *CACNA1D* gene, encoding a voltage-gated calcium channel [13, 15, 16]. These variants directly cause increased calcium influx through the mutant channel. Mutations in the Na^+/K^+ ATPase subunit gene *ATP1A1* account for approximately 5% of tumors, and mutations in the plasma membrane Ca^{2+} ATPase gene *ATP2B3* for a small percentage (about 2%) [13, 16, 17]. These variants cause abnormal permeability to sodium or proton ions, leading to depolarization similar to *KCNJ5* mutations [16, 18]. Lastly, mutations in the *CTNNB1* gene encoding beta catenin are found in 2–5% of tumors [19–21].

Important insight into the origin of APAs came from the description of subcapsular aldosterone-producing cell clusters (APCCs) that are found in normal adult adrenal glands. These clusters also carry somatic variants in the *CACNA1D* and *ATP1A1* genes [22] (► **Fig. 1**), suggesting that they represent precursors of APAs carrying such variants [23].

Familial aggregation of primary aldosteronism was initially reported in a father and his son with glucocorticoid-remediable aldosteronism (GRA, FH-I) [24]. GRA is due to unequal cross over between *CYP11B1*, encoding 11 β -hydroxylase involved in cortisol production under the control of adrenocorticotropic hormone (ACTH), and *CYP11B2*, encoding aldosterone synthase [25]. This leads to ACTH-dependent aldosterone production in the zona fasciculata. Following the discovery of somatic *KCNJ5* and *CACNA1D* mutations in APAs, inherited or de novo germline variants in the same genes were identified in FH-III [11, 26, 27] and PA with seizures and neurologic abnormalities (PASNA) syndrome [15],

respectively. Lastly, germline *CACNA1H* variants, which cause gain of function of the encoded calcium channel, were discovered in FH-IV [28].

The Known Unknowns

Despite the significant progress in understanding PA, several questions remain unanswered. One of the most obvious "known" questions is the genetic basis of the about 40% of aldosterone-producing adenomas without mutations in *KCNJ5*, *CACNA1D*, *ATP1A1*, *ATP2B3*, and *CTNNB1*. Several not mutually exclusive explanations come to mind.

The first explanation is of technical nature. APAs can demonstrate intra-tumor heterogeneity. Some tumor areas can be positive for aldosterone synthase expression by immunohistochemistry, whereas others are not, and variants are only found in aldosterone synthase positive areas [29]. Because not all tumor areas may carry disease-causing variants and biopsies can be contaminated with surrounding normal tissue and/or stroma, variant allele frequencies can be below Sanger sequencing detection levels. This explains why variants are occasionally found by next-generation sequencing in tumors that are negative by Sanger sequencing [19]. Analysis of large genes with variants scattered throughout the gene, such as *CACNA1D*, is particularly challenging by Sanger sequencing, and many studies have only analyzed part of the gene, so mutation frequencies may have been underestimated. APAs are also not always single circumscribed tumors. Surrounding hyperplasia and multinodular glands have also been described [5, 19], and in the absence of aldosterone synthase immunohistochemistry, it can be difficult to distinguish non-producing nodules from those producing aldosterone. Taken together, studies performed on tissue biopsies without immunohistochemistry against aldosterone synthase may have underestimated "true" mutation frequencies.

The second explanation would be that variants in additional genes that are only mutated in a small fraction of samples have so far evaded detection by exome sequencing. One would expect the finding of recurrent variants in the same gene in at least two independent tumor samples to support a role in pathogenesis. If mutations in an unknown gene are present in 5% of the samples, the binomial probability of finding mutations in at least two samples (assuming perfect sensitivity of the assay) is about 96% when 100 samples are sequenced. This likelihood drops to 72% with 50 samples sequenced, and 36% with 25 samples sequenced. These considerations suggest that a meta-analysis of exome sequencing studies from different groups may reveal additional genes involved in APA pathogenesis.

Third, copy number variation (CNV) has been described in APAs [11], but its role in the pathophysiology of APAs remains unclear. CNV may well account for a fraction of APAs, and the identification of one or several overlapping areas of CNV between tumors may point to key pathways involved in aldosterone production and/or proliferation. Another possibility is the co-occurrence of predisposing single-nucleotide variants (SNVs) in the germline and CNV in corresponding tumor samples – adrenals with several APAs and/or accompanying hyperplasia might be good candidates for such a disease mechanism.




Fig. 1 Genetics of PA – Open Questions: The genetic basis of sporadic bilateral adrenal hyperplasia (BAH) is unsolved. In addition to known Mendelian forms PA, there likely are several unknown syndromes to be discovered. Several genes show somatic single nucleotide variants (SNVs) or small insertions/deletions (indels) in aldosterone-producing adenomas (APAs). Some of these tumors likely arise from aldosterone-producing cell clusters (APCCs), but the origin of *KCNJ5* mutation-positive tumors, the largest subgroup, is unsolved. Similarly, the role of *CTNNB1* variants in APAs remains unclear. There are likely variants in additional genes to be discovered, and the role of copy-number variation (CNV) in APAs also remains to be characterized.

Another open question is the role of *CTNNB1* mutations in APAs. It is stunning that *CTNNB1* variants are found in non-producing adrenal adenomas, adrenocortical carcinomas, cortisol-producing adenomas as well as APAs [19–21, 30–34]. Some cortisol-producing adenomas with *CTNNB1* variants show additional *GNAS* variants, which explain hormone production [34, 35], but so far, no mutations in second genes have been described in APAs with *CTNNB1* variants. One group suggested an association of APAs with *CTNNB1* mutations with pregnancy, presumably due to expression and activation of gonadal receptors [36], but this seems highly unlikely because about 25 % of *CTNNB1*-positive tumors occur in males, and because these variants are more common in post-menopausal females than in pregnant women [20, 21, 37]. Similarly, expression of gonadal receptors as well as *CYP11B2* was subsequently shown to be heterogeneous [21]. Taken together, these findings suggest that *CTNNB1* variants may cause adrenal proliferation by activating Wnt signaling, but not excessive hormone production. The factors driving aldosterone production remain to be discovered.

Lastly, open questions concern the origin of *KCNJ5*-positive tumors. It has been suggested early on and confirmed that these tumors are histologically different from tumors with mutations in other genes; they tend to have a more fasciculata-like appearance [16, 19, 38]. It is therefore interesting that *KCNJ5* variants are not found in APCCs [22]. Do *KCNJ5*-positive tumors arise from zona fasciculata [38]? Do they grow so fast that precursors evade detection as APCCs? Related to this question, it is unclear why *KCNJ5* muta-

tions are more prevalent in females than in males in European and some Asian cohorts [12]. A higher mutation rate seems unlikely given that such female preponderance is absent in those with other mutations [13, 17]. An effect of gonadal steroids on proliferation or hormone production may play a role.

Another area of „known unknowns“ is the genetic basis of FH. There are a number of unsolved kindreds and/or cases. These include an extended kindred with so-called FH-II (non-glucocorticoid remediable aldosteronism) described in 1992 [39, 40], but also many additional cases of childhood-onset PA. In one analysis, a *CACNA1H* variant was identified in five of 40 unrelated subjects with hypertension due to PA by age 10 years [28], yet the remaining cases are unsolved. Whereas there is no proof that aldosteronism in these cases is Mendelian, the index of suspicion is high. APAs are increasingly rare in the pediatric age range, as is sporadic bilateral adrenal hyperplasia. These observations suggest that there are likely additional genes to be discovered in FH. Incomplete penetrance, small kindreds and the presence of phenocopies (subjects with sporadic PA in the family) are potential challenges in the analysis.

The Unknown Unknowns

The major “unknown unknown” is a potential genetic basis of sporadic BAH, also known as idiopathic hyperaldosteronism. Patients with BAH may show nodular changes on adrenal CT imaging, or CT

may be normal [4]. Because these patients typically do not undergo surgery, BAH is a histologically ill-defined entity. If the diagnosis is based on adrenal venous sampling showing bilateral aldosterone production [4], potential correlations may include bilateral microscopic hyperplasia, bilateral nodular hyperplasia, bilateral adenomas [41, 42], bilateral APCCs or any combination of these entities.

Thus, genetic contributions could include somatic variants in adenomas or APCCs, or predisposing germline variants. Non-genetic causes may include hypothetical serum factors or auto-antibodies against the angiotensin II type 1 receptor [43].

How could potential genetic contributors be studied? One approach would be to perform next-generation sequencing of lesions in the rare cases that have undergone surgery and search for somatic variants [42]. This may include cases operated based on presumed lateralization without cure [44]. Another option would be to study adrenals from autopsies – perhaps patients with known BAH could be part of a study that involves post-mortem removal of adrenal glands, or autopsy cases with BAH positive for aldosterone synthase expression could be studied. A case report suggests that elevated aldosterone levels can be determined from post-mortem blood [45], although reference ranges would have to be determined. Post mortem urinary aldosterone may also prove useful. Perhaps assessment of the juxtaglomerular apparatus could serve to distinguish primary from secondary aldosteronism [46]. Regarding potential germline variants, whether genome-wide association studies (GWAS) or next-generation sequencing studies would be helpful remains to be determined. Prior GWAS studies have focused on aldosterone to renin ratio in a population-based cohort (not PA) [47] or candidate gene association with aldosterone levels [48].

Outlook

The expected progress in solving unanswered questions in the genetic basis of PA over the next few years seems straightforward regarding the “known unknowns”. We will likely see the discovery of genetic variants in one or several additional genes that explain a small fraction of APAs, and we will likely see a better characterization of CNVs in APAs. This is expected to result in new insight into the pathophysiology of APAs and PA. We should also anticipate the discovery of variants in (a) new gene(s) in FH, with similar pathophysiological implications. Future animal models may help to better understand the development of *KCNJ5*-mutant tumors.

Much more difficult to predict is the progress on the genetic basis of bilateral adrenal hyperplasia, although a contribution of somatic variants seems possible. In any case, the exciting times of genetic discoveries in PA will likely continue.

Acknowledgements

U.I.S. is supported by grants of the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, Germany (NRW-Rückkehrprogramm, Junges Kolleg), the Deutsche Forschungsgemeinschaft (SCHO 1386/2-1) and the Fritz Thyssen Stiftung (10.16.1.027MN).

Conflict of Interest

The author is listed as an inventor on a patent application by Yale University (Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated with Mutant *KCNJ5*).

References

- [1] Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. *J Am Coll Cardiol* 2017; 69: 1811–1820
- [2] Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 2006; 48: 2293–2300
- [3] Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. *Hypertension* 2003; 42: 161–165
- [4] Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2016; 101: 1889–1916
- [5] Fernandes-Rosa FL, Giscos-Douriez I, Amar L, Gomez-Sanchez CE, Meatchi T, Boulkroun S, Zennaro MC. Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma. *Hypertension* 2015; 66: 1014–1022
- [6] Iacobone M, Citton M, Viel G, Boetto R, Bonadio I, Tropea S, Mantero F, Rossi GP, Fassina A, Nitti D, Favia G. Unilateral adrenal hyperplasia: A novel cause of surgically correctable primary hyperaldosteronism. *Surgery* 2012; 152: 1248–1255
- [7] Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. *Endocr Relat Cancer* 2005; 12: 149–159
- [8] Korah HE, Scholl UI. An update on familial hyperaldosteronism. *Horm Metab Res* 2015; 47: 941–946
- [9] Funder JW. Primary aldosteronism: New answers, new questions. *Horm Metab Res* 2015; 47: 935–940
- [10] DoD News Briefing. February 12, 2002; <http://archive.defense.gov/Transcripts/Transcript.aspx?TranscriptID=2636>. Accessed 09/03, 2017
- [11] Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang W, Carling T, Lifton RP. K⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science* 2011; 331: 768–772
- [12] Lenzi L, Rossitto G, Maiolino G, Letizia C, Funder JW, Rossi GP. A Meta-Analysis of Somatic *KCNJ5* K Channel Mutations In 1636 Patients with an aldosterone-producing adenoma. *J Clin Endocrinol Metab* 2015; jc20152149
- [13] Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, Monticone S, Amar L, Meatchi T, Mantero F, Cicala MV, Quinkler M, Fallo F, Allolio B, Bernini G, Maccario M, Giacchetti G, Jeunemaitre X, Mulatero P, Reincke M, Zennaro MC. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. *Hypertension* 2014; 64: 354–361
- [14] Spat A, Hunyady L. Control of aldosterone secretion: A model for convergence in cellular signaling pathways. *Physiol Rev* 2004; 84: 489–539

- [15] Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerstrom G, Bjorklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. *Nat Genet* 2013; 45: 1050–1054
- [16] Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. *Nat Genet* 2013; 45: 1055–1060
- [17] Beuschlein F, Boukroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilens B, Zennaro MC, Strom TM, Reincke M. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. *Nat Genet* 2013; 45: 440–444
- [18] Tauber P, Aichinger B, Christ C, Stindl J, Rhayem Y, Beuschlein F, Warth R, Bandulik S. Cellular Pathophysiology of an Adrenal Adenoma-Associated Mutant of the Plasma Membrane Ca(2+)-ATPase ATP2B3. *Endocrinology* 2016; 157: 2489–2499
- [19] Scholl UI, Healy JM, Thiel A, Fonseca AL, Brown TC, Kunstman JW, Horne MJ, Dietrich D, Riemer J, Kucukkoyslu S, Reimer EN, Reis AC, Goh G, Kristiansen G, Mahajan A, Korah R, Lifton RP, Prasad ML, Carling T. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. *Clin Endocrinol (Oxf)* 2015; 83: 779–789
- [20] Akerstrom T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, Moser A, Stalberg P, Robinson B, Alexander Iwen K, Dralle H, Walz MK, Lehnert H, Sidhu S, Gomez-Sanchez C, Hellman P, Bjorklund P. Activating mutations in CTNNB1 in aldosterone producing adenomas. *Sci Rep* 2016; 6: 19546
- [21] Wu VC, Wang SM, Chueh SJ, Yang SY, Huang KH, Lin YH, Wang JJ, Connolly R, Hu YH, Gomez-Sanchez CE, Peng KY, Wu KD. The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes. *Sci Rep* 2017; 7: 39121
- [22] Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, Liu CJ, Sanjanwala AR, Edwards MA, Gomez-Sanchez CE, Nanba K, Rainey WE. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. *Proc Natl Acad Sci U S A* 2015; 112: E4591–E4599
- [23] Nishimoto K, Seki T, Kurihara I, Yokota K, Omura M, Nishikawa T, Shibata H, Kosaka T, Oya M, Suematsu M, Mukai K. Case report: Nodule development from subcapsular aldosterone-producing cell clusters causes hyperaldosteronism. *J Clin Endocrinol Metab* 2016; 101: 6–9
- [24] Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. *Can Med Assoc J* 1966; 95: 1109–1119
- [25] Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ullick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. *Nature* 1992; 355: 262–265
- [26] Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. *Proc Natl Acad Sci U S A* 2012; 109: 2533–2538
- [27] Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S, Penton D, Plouin PF, Warth R, Allolio B, Jeunemaitre X, Veglio F, Reincke M. KCNJ5 mutations in European families with non-glucocorticoid remediable familial hyperaldosteronism. *Hypertension* 2012; 59: 235–240
- [28] Scholl UI, Stolting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. *eLife* 2015; 4:
- [29] Nanba K, Chen AX, Omata K, Vinco M, Giordano TJ, Else T, Hammer GD, Tomlins SA, Rainey WE. Molecular heterogeneity in aldosterone-producing adenomas. *J Clin Endocrinol Metab* 2016; 101: 999–1007
- [30] Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, Rene-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papatomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libe R, de Reynies A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. *Nat Genet* 2014; 46: 607–612
- [31] Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libe R, Rene-Corail F, Audebourg A, Vacher-Lavenu MC, Groussin L, Bertagna X, Dousset B, Bertherat J, Tissier F. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. *J Clin Endocrinol Metab* 2011; 96: E419–E426
- [32] Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW, Korah R, Suttrop AC, Dietrich D, Haase M, Willenberg HS, Stalberg P, Hellman P, Akerstrom G, Bjorklund P, Carling T, Lifton RP. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. *Nat Genet* 2014; 46: 613–617
- [33] Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Backdahl M, Suttrop AC, Haase M, Choi M, Schlessinger J, Rimm DL, Hoog A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. *J Clin Endocrinol Metab* 2015; 100: E493–E502
- [34] Thiel A, Reis AC, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI. PRKACA mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center study of 60 cases. *Eur J Endocrinol* 2015; 172: 677–685
- [35] Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, Zhou W, Li X, Zhong X, Lei Y, Su T, Wang H, Jiang Y, Yang L, Wei W, Yang X, Jiang X, Liu L, He J, Ye J, Wei Q, Li Y, Wang W, Wang J, Ning G. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. *Science* 2014; 344: 913–917
- [36] Teo AE, Garg S, Haris Shaikh L, Zhou J, Karet Frankl FE, Gurnell M, Happerfield L, Marker A, Bienz M, Azizan EA, Brown MJ. Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations. *N Engl J Med* 2015; 373: 1429–1436
- [37] Murtha TD, Carling T, Scholl UI. Pregnancy, Primary Aldosteronism, and Somatic CTNNB1 Mutations. *N Engl J Med* 2016; 374: 1492–1493
- [38] Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. *J Clin Endocrinol Metab* 2012; 97: E819–E829

- [39] Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. *Clin Exp Pharmacol Physiol* 1992; 19: 319–322
- [40] Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F, Stowasser M. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. *J Hypertens* 2008; 26: 1577–1582
- [41] Morimoto R, Satani N, Iwakura Y, Ono Y, Kudo M, Nezu M, Omata K, Tezuka Y, Seiji K, Ota H, Kawasaki Y, Ishidoya S, Nakamura Y, Arai Y, Takase K, Sasano H, Ito S, Satoh F. A case of bilateral aldosterone-producing adenomas differentiated by segmental adrenal venous sampling for bilateral adrenal sparing surgery. *J Hum Hypertens* 2016; 30: 379–385
- [42] Wu VC, Chueh SC, Chang HW, Lin WC, Liu KL, Li HY, Lin YH, Wu KD, Hsieh BS. Bilateral aldosterone-producing adenomas: Differentiation from bilateral adrenal hyperplasia. *QJM* 2008; 101: 13–22
- [43] Li H, Yu X, Cicala MV, Mantero F, Benbrook A, Veitla V, Cunningham MW, Kem DC. Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism. *J Am Soc Hypertens* 2015; 9: 15–20
- [44] Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr., Gomez-Sanchez CE, Funder JW, Reincke M. Primary Aldosteronism Surgery Outcome i. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. *Lancet Diabetes Endocrinol* 2017; 5: 689–699
- [45] Palmiere C, Lesta Mdel M, Sabatasso S, Mangin P, Augsburg M, Sporkert F. Usefulness of postmortem biochemistry in forensic pathology: Illustrative case reports. *Leg Med (Tokyo)* 2012; 14: 27–35
- [46] Parker RA. Distribution of the changes in the juxtaglomerular apparatus in human renal artery stenosis. *Nephron* 1967; 4: 315–325
- [47] Spyroglou A, Bozoglu T, Rawal R, De Leonardis F, Sterner C, Boulkroun S, Benecke AG, Monti L, Zennaro MC, Petersen AK, Doring A, Rossi A, Bidlingmaier M, Warth R, Gieger C, Reincke M, Beuschlein F. Diastrophic dysplasia sulfate transporter (SLC26A2) is expressed in the adrenal cortex and regulates aldosterone secretion. *Hypertension* 2014; 63: 1102–1109
- [48] Manichaikul A, Rich SS, Allison MA, Guagliardo NA, Bayliss DA, Carey RM, Barrett PQ. KCNK3 variants are associated with hyperaldosteronism and hypertension. *Hypertension* 2016; 68: 356–364